Altre lingue Pieris Pharmaceuticals, Inc.

Azioni

PIRS

US7207952026

Tempo differito Nasdaq Altri mercati azionari 15:52:00 01/05/2024			Variaz. 5gg	Var. 1 gen.
11,94 ^USD	+1,96%		+0,08%	-17,99%

29/03	Pieris Pharmaceuticals, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
05/01	Prime Medicine nomina il CFO di Foghorn Therapeutics come nuovo responsabile delle finanze	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split	22/04
Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement	19/04
Pieris Pharmaceuticals : Announces 1-for-80 Reverse Stock Split - Form 8-K	18/04
North American Morning Briefing : Powell Awaited -2-	03/04
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential	28/03
Pieris Pharmaceuticals : Announces Strategy to Maximize Partnered Milestone and Royalty Potential - Form 8-K	27/03
North American Morning Briefing : Stocks Edge -2-	27/03
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief	05/01
North American Morning Briefing : Stocks Seen -2-	15/11
Pieris Pharmaceuticals: Q3 Earnings Snapshot	14/11
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
North American Morning Briefing : Stock Futures -2-	08/11
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from S&P Global BMI Index	18/09/23
Vicore Pharma's New CEO to Formally Take Office	08/09/23
Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma	04/09/23
Sweden’s Hansa Biopharma Appoints New Chief Scientific Officer	01/09/23
Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma	01/09/23
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific	18/08/23
Pieris Pharmaceuticals Says Patient Dosing in Cancer Drug Trial Triggers Milestone Payment From Boston Pharmaceuticals	17/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Pieris Pharmaceuticals, Inc.

Azioni

PIRS

US7207952026

Altre lingue

Filtri